The past and future of haemophilia: diagnosis, treatments, and its complications

Flora Peyvandi, Isabella Garagiola, Guy Young

Research output: Contribution to journalReview articlepeer-review


Haemophilia A and B are hereditary haemorrhagic disorders characterised by deficiency or dysfunction of coagulation protein factors VIII and IX, respectively. Recurrent joint and muscle bleeds lead to severe and progressive musculoskeletal damage. Existing treatment relies on replacement therapy with clotting factors, either at the time of bleeding (ie, on demand) or as part of a prophylactic schedule. The major complication of such therapy is the development of neutralising antibodies (ie, inhibitors), which is most frequent in haemophilia A. Treatment might improve considerably with the availability of new modified drugs, which might overcome existing prophylaxis limitations by reducing dosing frequency and thereby rendering therapy less distressing for the patient. Subcutaneous administration of some new therapies would also simplify prophylaxis in children with poor venous access. Gene therapy has the potential for a definitive cure, and important results have been obtained in haemophilia B. Despite improvements in haemophilia care, the availability of clotting factor concentrates for all affected individuals worldwide remains the biggest challenge.

Original languageEnglish
Pages (from-to)187-197
Number of pages11
JournalThe Lancet
Issue number10040
Publication statusPublished - Jul 9 2016

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'The past and future of haemophilia: diagnosis, treatments, and its complications'. Together they form a unique fingerprint.

Cite this